Real-world data on the effectiveness of risankizumab as induction therapy for ustekinumab-refractory ulcerative colitis
Intestinal Research · 10.08.2026
DOI: 10.5217/ir.2025.00338 ↗Kurz gefasst
Fachartikel in der Zeitschrift Intestinal Research, online erschienen am 10.08.2026. Verfasst von Ryo Morikawa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Institute of Science Tokyo, Tokyo, Japan. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
Ulcerative colitis (UC) is a chronic inflammatory bowel disease resulting from inappropriate immune responses and is characterized by diarrhea and bloody stools. Currently, numerous biologics and small-molecule agents have been developed and have improved outcomes in patients with UC. 1 Interleukin-23 (IL-23), a heterodimeric cytokine composed of p19 and p40 subunits, plays an important role in inflammatory bowel disease pathogenesis. 2 Risankizumab (RZB) is a monoclonal antibody targeting the IL-23 p19 subunit, and its efficacy in treating UC has been demonstrated in a phase 3 clinical trial. 3 However, unlike the phase 3 trial for Crohn’s disease, 4,5 the trial for UC did not examine patients with prior exposure to ustekinumab (UST). Consequently, the efficacy of RZB in such patients remains unclear. Therefore, this study aimed to evaluate the short-term real-world efficacy of RZB in patients with UC previously treated with UST at our institution. This retrospective cohort study included patients with UC who were previously exposed to UST and were initiated on RZB therapy between July 2024 and August 2025
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Institute of Science Tokyo, Tokyo, Japan.
- Department of Gastroenterology and Hepatology, Institute of Science Tokyo, Tokyo, Japan. tfujii.gast@tmd.ac.jp.
Zitieren
APA
Morikawa, R., Fujii, T., Tamura, A., Kawamoto, A., Hibiya, S., Takenaka, K., Shimizu, H., Ohtsuka, K., & Okamoto, R. (2026). Real-world data on the effectiveness of risankizumab as induction therapy for ustekinumab-refractory ulcerative colitis. Intestinal Research. https://doi.org/10.5217/ir.2025.00338
Vancouver
Morikawa R, Fujii T, Tamura A, Kawamoto A, Hibiya S, Takenaka K, et al. Real-world data on the effectiveness of risankizumab as induction therapy for ustekinumab-refractory ulcerative colitis. Intestinal Research. 2026. doi:10.5217/ir.2025.00338
BibTeX
@article{Morikawa2026,
author = {Morikawa, Ryo and Fujii, Toshimitsu and Tamura, Akiko and Kawamoto, Ami and Hibiya, Shuji and Takenaka, Kento and Shimizu, Hiromichi and Ohtsuka, Kazuo and Okamoto, Ryuichi},
title = {Real-world data on the effectiveness of risankizumab as induction therapy for ustekinumab-refractory ulcerative colitis},
journal = {Intestinal Research},
year = {2026},
doi = {10.5217/ir.2025.00338}
}
EUVIMED